Plasma metabolomic profile varies with glucocorticoid dose in patients with congenital adrenal hyperplasia.

ABSTRACT: Glucocorticoid replacement therapy is the mainstay of treatment for congenital adrenal hyperplasia (CAH) but has a narrow therapeutic index and dose optimisation is challenging. Metabolomic profiling was carried out on plasma samples from 117 adults with 21-hydroxylase deficiency receiving their usual glucocorticoid replacement therapy who were part of the CaHASE study. Samples were profiled by using hydrophilic interaction chromatography with high resolution mass spectrometry. The patients were also profiled using nine routine clinical measures. The data were modelled by using both multivariate and univariate statistics by using the clinical metadata to inform the choice of patient groupings. Comparison of 382 metabolites amongst groups receiving different glucocorticoid doses revealed a

SUBMITTER: Alwashih MA 

PROVIDER: S-EPMC5719028 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature